Neola Medical AB (NEOLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neola Medical AB (NEOLA) has a cash flow conversion efficiency ratio of -0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.77 Million ≈ $-406.25K USD) by net assets (Skr75.80 Million ≈ $8.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Neola Medical AB to measure how many days the company can operate on defensive assets alone.
Neola Medical AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Neola Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neola Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neola Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Q Interline AS
CO:QINTER
|
-3.097x |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
-0.216x |
|
Bright Packaging Industry Bhd
KLSE:9938
|
0.026x |
|
Enduro Metals Corp
V:ENDR
|
-0.005x |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
-0.292x |
|
Moonpig Group PLC
LSE:MOON
|
-0.276x |
|
Muza S.A
WAR:MZA
|
0.019x |
|
Paranapanema S.A
SA:PMAM3
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Neola Medical AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Neola Medical AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see NEOLA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr75.80 Million ≈ $8.16 Million |
Skr-11.95 Million ≈ $-1.29 Million |
-0.158x | -0.34% |
| 2024-12-31 | Skr68.96 Million ≈ $7.42 Million |
Skr-10.84 Million ≈ $-1.17 Million |
-0.157x | -89.83% |
| 2023-12-31 | Skr79.03 Million ≈ $8.50 Million |
Skr-6.54 Million ≈ $-704.02K |
-0.083x | +34.25% |
| 2022-12-31 | Skr67.48 Million ≈ $7.26 Million |
Skr-8.50 Million ≈ $-914.41K |
-0.126x | +26.18% |
| 2021-12-31 | Skr40.63 Million ≈ $4.37 Million |
Skr-6.93 Million ≈ $-745.89K |
-0.171x | +33.89% |
| 2020-12-31 | Skr23.55 Million ≈ $2.53 Million |
Skr-6.08 Million ≈ $-653.77K |
-0.258x | -33.84% |
| 2019-12-31 | Skr10.72 Million ≈ $1.15 Million |
Skr-2.07 Million ≈ $-222.44K |
-0.193x | -94.79% |
| 2018-12-31 | Skr13.33 Million ≈ $1.43 Million |
Skr-1.32 Million ≈ $-141.95K |
-0.099x | -- |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume chan… Read more